$RZLT News

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

Rezolute Highlights ENDO Data On Congenital HI Outcomes And Tumor HI Case Series Supporting Ersodetug Program

Guggenheim Maintains Buy on Rezolute, Raises Price Target to $11

Positive Signs As Multiple Insiders Buy Rezolute Stock

RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Rezolute To Present Four Presentations At Upcoming Annual Meeting Of Endocrine Society

Maxim Group Maintains Buy on Rezolute, Raises Price Target to $14

Rezolute’s stock up on interim Phase III tumour HI data

Citizens Upgrades Rezolute to Market Outperform, Announces $11 Price Target

Wedbush Maintains Outperform on Rezolute, Raises Price Target to $6

Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

HC Wainwright & Co. Reiterates Buy on Rezolute, Maintains $5 Price Target

Rezolute Reports Mid-Study Results for Rare Hypoglycemia Treatment

Maxim Group Maintains Buy on Rezolute, Raises Price Target to $10

Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

Rezolute Q3 EPS $(0.16), Inline

Rezolute to Participate in Upcoming Investor Conferences

Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting